相关实验视频

Updated: Sep 9, 2025

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

在帕金森病患者的红细胞中,α-synuclein增加

Ryan N Coyle¹, Anne M Roberts^1,2, Malcolm Horne³

¹Department of Biochemistry, Emory University, Atlanta, GA, 30322, USA.

Scientific reports

|August 29, 2025

概括

异常性帕金森病 (iPD) 显示红细胞 (红细胞) 中的α-syn核素水平升高. 然而,这些红细胞α-syn水平单独不足以诊断iPD.

科学领域:

神经科学
生物化学
生物标志物发现

背景情况:

固态帕金森病 (iPD) 是一种常见的神经退行性疾病.
阿尔法-同核素 (α-syn) 聚合是IPD的一个关键病理标志.
与阿尔茨海默病 (AD) 不同,目前IPD的诊断方法缺乏有效的基于血液的生物标志物.

研究的目的:

调查红细胞α-syn核素 (α-syn) 水平作为异常性帕金森病 (iPD) 的血液生物标志物的潜力.
在IPD患者,AD患者和健康对照者 (CN) 中比较α-syn水平.

主要方法:

使用向液态染色体质谱法 (LC-MS) 试验.
包括以15N丰富的重组α-syn作为内部量化标准.
在IPD,AD和CN组的红细胞中测量和比较α-syn度.

主要成果:

与健康对照人群相比,红细胞α- syn度显著升高 (48. 1μg mL- 1).
在AD患者 (33. 5μg mL−1) 和健康对照人群之间没有观察到红细胞α- syn水平的显著差异.
受体操作特征 (ROC) 分析显示曲线下的面积 (AUC) 为0. 62,表明单独的红细胞α-syn的诊断效用有限.

结论:

与对照患者相比,红细胞含有显著更高的α-syn.
仅仅是红细胞α-syn水平不足以准确诊断iPD.
需要进行进一步的研究,以探索组合生物标志物,以改进IPD诊断.

关键词:

阿尔法同核素红细胞帕金森病蛋白质组学其他国家红细胞

更多相关视频

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

相关概念视频

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...